-
Pimodivir
- names:
Pimodivir
- CAS号:
1629869-44-8
MDL Number: - MF(分子式): C20H19F2N5O2 MW(分子量): 399.39
- EINECS: Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
| 货品编码 | 规格 | 纯度 | 价格 (¥) | 现价(¥) | 特价(¥) | 库存描述 | 数量 | 总计 (¥) |
|---|---|---|---|---|---|---|---|---|
| YZM000729-5mg | 5mg | 99.04% | ¥ 2092.50 | ¥ 2092.50 | 2-3天 | ¥ 0.00 | ||
| YZM000729-2mg | 2mg | 99.04% | ¥ 1287.00 | ¥ 1287.00 | 2-3天 | ¥ 0.00 |
| 中文别名 | |
| 英文别名 | Pimodivir |
| CAS号 | 1629869-44-8 |
| Inchi | |
| InchiKey | |
| 分子式 Formula | C20H19F2N5O2 |
| 分子量 Molecular Weight | 399.39 |
| 溶解度Solubility | 生物体外In Vitro:DMSO溶解度100 mg/mL(250.38 mM;Need ultrasonic) |
| 性状 | |
| 储藏条件 Storage conditions | 粉末Powder: -20°C 3 years年 4°C 2 years年 / In solvent溶液中:-80°C 6 months月 -20°C 1 month月 |
| 产品说明 | |
| Introduction | Pimodivir (VX87) is an orally bioavailable inhibitor ofinfluenza A virus polymerasesthrough interaction with the viralPB2subunit. |
| Application1 | |
| Application2 | |
| Application3 |
Pimodivir (VX-787) 是一种有效的可口服的甲型流感病毒聚合酶抑制剂,通过抑制PB2亚基起作用。Pimodivir (VX-787) is an orally bioavailable inhibitor ofinfluenza A virus polymerasesthrough interaction with the viralPB2subunit.
【1】.Smee DF, et al. Activities of JNJ63623872 and oseltamivir against influenza A H1N1pdm and H3N2 virus infections in mice. Antiviral Res. 2016 Dec;136:45-50.
【2】.Fu Y, et al. JNJ872 inhibits influenza A virus replication without altering cellular antiviral responses. Antiviral Res. 2016 Sep;133:23-31.
【3】.Boyd MJ, et al. Isosteric replacements of the carboxylic acid of drug candidate VX-787: Effect of charge on antiviral potency and kinase activity of azaindole-based influenza PB2 inhibitors. Bioorg Med Chem Lett. 2015 May 1;25(9):1990-4.
【4】.Byrn RA, et al. Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit. Antimicrob Agents Chemother. 2015 Mar;59(3):1569-82.
【2】.Fu Y, et al. JNJ872 inhibits influenza A virus replication without altering cellular antiviral responses. Antiviral Res. 2016 Sep;133:23-31.
【3】.Boyd MJ, et al. Isosteric replacements of the carboxylic acid of drug candidate VX-787: Effect of charge on antiviral potency and kinase activity of azaindole-based influenza PB2 inhibitors. Bioorg Med Chem Lett. 2015 May 1;25(9):1990-4.
【4】.Byrn RA, et al. Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit. Antimicrob Agents Chemother. 2015 Mar;59(3):1569-82.
对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
- 相关产品
-
< >
- 推荐产品
-
< >
- 最新产品
-
< >
新闻
抱歉,暂无数据!


购物车 


